PTC Therapeutics (PTCT) 10-Q2018 Q2 Quarterly report

Filed: 7 Aug 18, 4:46pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: abdominal, abnormal, acute, Agility, akcea, Alnylam, amyloid, Angelman, antigravity, antisense, antitrust, anxiety, ASO, assumption, ataxia, autonomic, Biotech, bone, brain, break, capacity, cardiomyopathy, Caribbean, Children, chylomicronemia, clearance, Colorado, consummate, consummated, consummation, cured, daily, death, debilitating, dysfunction, emotional, Endocrinology, familial, fatal, fatigue, FCS, fifteen, fog, footage, formation, FPL, Friedreich, guarantor, hATTR, heart, hereditary, hypertriglyceridemia, inconsistent, indirect, inherited, inhibitor, injection, innovative, inotersen, internationally, intestinal, issuable, LATAM, lipase, lipodystrophy, lipoprotein, LPL, magnitude, marrow, metreleptin, monogenic, nonemployee, Novelion, oligonucleotide, onset, overlapping, overseen, pain, patisiran, penalty, percent, peripheral, Pfizer, phenotype, Philadelphia, polyneuropathic, polyneuropathy, preliminarily, prepay, psychosocial, real, remedy, repaid, risdiplam, ROFN, score, sensory, shortfall, social, SOM, sponsorship, Steering, symptom, Tegsedi, TegsediTM, thereon, thyroid, tolcapone, tract, Transitory, transthyretin, TTR, underestimated, undergo, video, virtue, volanesorsen, voucher, waiting, waiver, WAYLIVERA, Waylivra, WaylivraTM, WAYLIVRTM

Removed: accurate, affecting, alter, Brexit, bribery, care, collecting, commonly, Corrupt, devalue, difficulty, diminished, dollar, emerging, euro, exiting, export, exposure, fall, favor, group, impacted, import, individually, inherently, instability, Kingdom, labor, local, pound, prescribed, purview, qualified, regional, regulation, screening, spend, staffing, sterling, UK, Union, unrest, vulnerable, younger

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated PTCT transcripts

PTCT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of PTC Therapeutics, Inc. (the “Company”) for the period ended June 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Christine Utter, Principal Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date: August 7, 2018	By:	/s/ CHRISTINE UTTER
		Christine Utter
		Principal Financial Officer
		(Principal Financial and Accounting Officer)